In this year’s quarterly report and last year’s annual report, the performance of in vitro diagnostic companies such as Shengxiang Biotech and Daan Genes ushered in collective high growth. From the overall perspective of the sector, six of the top ten net profit growth in the medical device sector were in vitro Diagnose the enterprise. During the epidemic, companies in the IVD industry continued to go public and a large number of financing incidents occurred. Data show that my country has become one of the fastest growing markets for in vitro diagnostics in the world. The new crown epidemic has given more Chinese IVD products the opportunity to go abroad.

Chairman Song Haibo stated that as of the end of April 2021, a total of 59 new crown testing reagent products in my country, 43 manufacturers have obtained product registration certificates from the State Food and Drug Administration, and 620 products have obtained export licenses. This epidemic is extremely It has greatly improved the R&D and production capabilities of my country's IVD companies, and at the same time greatly enhanced the influence of my country's IVD companies in the international arena. Although my country's in vitro diagnostic industry started relatively late, its development speed is as fast as pressing the accelerator key.

Hu Xuhui, chairman of Yahuilong Biological, said that Yahuilong achieved a 50% growth rate against the trend last year. In the first quarter of this year, it also achieved a larger growth rate compared with the first quarter of last year. Last year, the company’s new crown detection reagents and The export value of the instrument to the company is about RMB 90,000,000.

Gong Weibin, director of Yahuilong Bio-Supply Chain Center, said that Yahuilong’s export demand has simultaneously increased by three times. When the epidemic broke out in March and April last year, with the support of all employees for production, normal production capacity was tripled.